A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.
Finasteride may affect blood sugar and metabolism, with some users reporting increased blood sugar and changes in body composition. To manage potential side effects, users suggest exercise, intermittent fasting, and dietary adjustments.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.
People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.